You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmitriptyline
Accession NumberDB00321  (APRD00227)
TypeSmall Molecule
GroupsApproved
DescriptionAmitriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amitriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, amitriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amitriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).
Structure
Thumb
Synonyms
10,11-dihydro-5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-dihydro-N,N-Dimethyl-5H-dibenzo(a,D)heptalene-delta(5),gamma-propylamine
3-(10,11-dihydro-5H-Dibenzo(a,D)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
Amitriptilina
Amitriptylin
Amitriptyline
Amitriptylinum
External Identifiers
  • MK 230
  • N 750
  • Ro 4-1575
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmitriptylineTablet25 mgOralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
AmitriptylineTablet50 mgOralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
AmitriptylineTablet10 mgOralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
Amitriptyline 10 TabTablet10 mgOralDuchesnay Inc1981-12-312003-07-18Canada
Amitriptyline 25 TabTablet25 mgOralDuchesnay Inc1981-12-312003-07-18Canada
Amitriptyline HCl Tab 25mgTablet25 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Amitriptyline HCl Tab 50mgTablet50 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Amitriptyline Tablets B.p 25mgTablet25 mgOralClonmel Healthcare Limited1992-12-311996-09-09Canada
Amitriptyline-10Tablet10 mgOralPro Doc Limitee1976-12-31Not applicableCanada
Amitriptyline-25Tablet25 mgOralPro Doc Limitee1976-12-31Not applicableCanada
Amitriptyline-50Tablet50 mgOralPro Doc Limitee1978-12-31Not applicableCanada
Bio-amitriptylineTablet50 mgOralBiomed Pharma2003-04-23Not applicableCanada
Bio-amitriptylineTablet10 mgOralBiomed Pharma2003-04-23Not applicableCanada
Bio-amitriptylineTablet25 mgOralBiomed Pharma2003-04-23Not applicableCanada
Dom-amitriptylineTablet10 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-amitriptylineTablet25 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-amitriptylineTablet50 mgOralBiomed Pharma2004-02-062013-08-02Canada
ElavilTablet25 mgOralAa Pharma Inc1975-12-31Not applicableCanada
ElavilTablet75 mgOralAa Pharma Inc1987-12-31Not applicableCanada
ElavilTablet50 mgOralAa Pharma Inc1975-12-31Not applicableCanada
ElavilTablet10 mgOralAa Pharma Inc1975-12-31Not applicableCanada
Elavil Pamoate Syr 10mg/5mlSyrup2 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-311998-08-14Canada
Elavil Tablet 10mgTablet10 mgOral1560678 Ontario Inc.1961-12-312003-08-02Canada
Elavil Tablet 25mgTablet25 mgOral1560678 Ontario Inc.1961-12-312003-08-02Canada
Elavil Tablet 50mgTablet50 mgOral1560678 Ontario Inc.1964-12-312010-05-05Canada
Elavil Tablet 75mgTablet75 mgOral1560678 Ontario Inc.1976-12-312010-05-05Canada
Ipg-amitriptylineTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylineTablet75 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylineTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylineTablet25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-amitriptylineTablet50 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-amitriptylineTablet75 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-amitriptylineTablet10 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-amitriptylineTablet25 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-amitriptyline TabletsTablet75 mgOralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline TabletsTablet10 mgOralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline TabletsTablet25 mgOralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline TabletsTablet50 mgOralJamp Pharma Corporation2015-01-12Not applicableCanada
LevateTablet10 mgOralBiomed Pharma1965-12-31Not applicableCanada
LevateTablet75 mgOralBiomed Pharma1979-12-31Not applicableCanada
LevateTablet25 mgOralBiomed Pharma1974-12-31Not applicableCanada
LevateTablet50 mgOralBiomed Pharma1969-12-31Not applicableCanada
Mar-amitriptylineTablet50 mgOralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Mar-amitriptylineTablet75 mgOralMarcan Pharmaceuticals Inc2015-04-27Not applicableCanada
Mar-amitriptylineTablet10 mgOralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Mar-amitriptylineTablet25 mgOralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Novo-triptyn Tab 10mgTablet10 mgOralNovopharm Limited1972-12-31Not applicableCanada
Novo-triptyn Tab 25mgTablet25 mgOralNovopharm Limited1972-12-31Not applicableCanada
Novo-triptyn Tab 50mgTablet50 mgOralNovopharm Limited1972-12-31Not applicableCanada
Nu-amitriptyline TabletsTablet75 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline TabletsTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline TabletsTablet25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline TabletsTablet50 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-amitriptylineTablet50 mgOralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptylineTablet10 mgOralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptylineTablet25 mgOralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptyline Tablets 10mgTablet10 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS-amitriptyline Tablets 25mgTablet25 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS-amitriptyline Tablets 50mgTablet50 mgOralPharmascience Inc1988-12-31Not applicableCanada
Teva-amitriptylineTablet10 mgOralTeva Canada Limited2014-12-03Not applicableCanada
Teva-amitriptylineTablet25 mgOralTeva Canada Limited2014-12-03Not applicableCanada
Teva-amitriptylineTablet50 mgOralTeva Canada Limited2014-12-03Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralPreferred Pharmaceuticals Inc.2016-06-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1Oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-10-31Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralH.J. Harkins Company, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralSandoz Inc1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralMylan Institutional Inc.1994-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralPhysicians Total Care, Inc.1995-07-25Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralBlenheim Pharmacal, Inc.2010-03-03Not applicableUs
Amitriptyline HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2010-12-132016-10-13Us
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralMed Vantx, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralPhysicians Total Care, Inc.1995-11-07Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralGLENVIEW PHARMA INC.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2015-03-03Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralUnit Dose Services2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1Oralbryant ranch prepack1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralLake Erie Medical DBA Quality Care Products LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2011-12-06Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralUnit Dose Services1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralSandoz Inc1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralNu Care Pharmaceuticals, Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralPreferred Pharmaceuticals Inc.2016-11-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralSandoz Inc1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralUnit Dose Services2014-12-26Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet25 mg/1Oralbryant ranch prepack2009-10-23Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralH.J. Harkins Company, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralPreferred Pharmaceuticals, Inc.1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2006-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralMylan Institutional Inc.1994-12-13Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralCardinal Health2011-06-17Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralDIRECT RX2015-01-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline HydrochlorideTablet150 mg/1OralREMEDYREPACK INC.2010-12-132016-10-13Us
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1994-10-04Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralGLENVIEW PHARMA INC.1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2015-03-25Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralMylan Institutional Inc.1994-02-15Not applicableUs
Amitriptyline HydrochlorideTablet50 mg/1OralSt. Mary's Medical Park Pharmacy2009-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1Oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralRebel Distributors Corp.1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralSTAT Rx USA LLC1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2012-09-172016-10-13Us
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-06-04Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralSandoz Inc1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralNu Care Pharmaceuticals, Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralRed Pharm Drug, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2011-10-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralSandoz Inc1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralUnit Dose Services2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1Oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralSTAT Rx USA LLC2009-11-19Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-03-02Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralH.J. Harkins Company, Inc.1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralUnit Dose Services1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralCarilion Materials Management1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2009-09-23Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralLake Erie Medical DBA Quality Care Products LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralCardinal Health2011-06-17Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralMedsource Pharmaceuticals2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralTYA Pharmaceuticals1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralSTAT Rx USA LLC1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralPhysicians Total Care, Inc.2003-02-04Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-06-04Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralMylan Institutional Inc.1994-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralREMEDYREPACK INC.2015-03-07Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralProficient Rx LP2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-05-31Not applicableUs
Amitriptyline HydrochlorideTablet, film coated150 mg/1OralREMEDYREPACK INC.2013-10-15Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralSandoz Inc1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralPreferred Pharamaceuticals Inc.2016-10-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralPhysicians Total Care, Inc.1996-06-18Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralGLENVIEW PHARMA INC.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralUnit Dose Services1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1Oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated75 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-24Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2010-12-16Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralProficient Rx LP2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralA S Medication Solutions1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralNu Care Pharmaceuticals, Inc.2016-09-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1Oralbryant ranch prepack1978-04-10Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralCardinal Health2011-06-17Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-06-02Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralTYA Pharmaceuticals1977-11-29Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralSTAT Rx USA LLC1977-11-21Not applicableUs
Amitriptyline HydrochlorideTablet, film coated25 mg/1OralBlenheim Pharmacal, Inc.2010-08-04Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralPhysicians Total Care, Inc.1999-09-13Not applicableUs
Amitriptyline HydrochlorideTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated100 mg/1OralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline HydrochlorideTablet25 mg/1OralDIRECT RX2014-01-01Not applicableUs
Amitriptyline HydrochlorideTablet, film coated50 mg/1OralMylan Institutional Inc.1994-10-26Not applicableUs
Apo-amitriptylineTablet25 mgOralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylineTablet50 mgOralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylineTablet75 mgOralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylineTablet10 mgOralApotex Inc2013-06-12Not applicableCanada
Elavil 25 mgTablet25 mg/1OralThompson Medical Solutions Llc1997-09-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Equipto - Amitriptyline External Cream Compounding KitKitTopicalAlvix Laboratories, LLC2015-01-20Not applicableUs
International Brands
NameCompany
AdeprilTeofarma
AmitrypRaza
ConmitripCondrugs
EndepAlphapharm
FiordaDriburg
KamitrinSaga
LaroxylDeva
LatilinLa Pharmaceuticals
MaxitripInvision
RedomexLundbeck
SarotenLundbeck
SarotexLundbeck
Sarotex RetardLundbeck
SyneudonKrewel Meuselbach
TryptanolMerck Sharp & Dohme
TryptanolSquare
TryptizolAlgorithm
Uxen RetardSanofi-Aventis
Brand mixtures
NameLabellerIngredients
Apo Peram Tab 2-25Apotex Inc
Apo Peram Tab 3-15Apotex Inc
Chlordiazepoxide and Amitriptyline HClPar Pharmaceutical Inc
Chlordiazepoxide and Amitriptyline HydrochlorideMylan Pharmaceuticals Inc.
Elavil Plus TabTriton Pharma Inc
Etrafon 2 10Schering Plough Canada Inc
Etrafon A TabSchering Plough Canada Inc
Etrafon D TabSchering Plough Canada Inc
Etrafon F TabSchering Plough Canada Inc
Perphenazine and Amitriptyline HydrochlorideREMEDYREPACK INC.
PMS-levazine 2/25 TabPharmascience Inc
PMS-levazine 3/15 TabPharmascience Inc
PMS-levazine 4/25 TabPharmascience Inc
Proavil TabPro Doc Limitee
Sentravil PM-25Physician Therapeutics Llc
Triavil TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Amitriptyline Hydrochloride
549-18-8
Thumb
  • InChI Key: KFYRPLNVJVHZGT-UHFFFAOYSA-N
  • Monoisotopic Mass: 313.15972748
  • Average Mass: 313.864
DBSALT000009
Amitriptyline Pamoate
17086-03-2
Thumb
  • InChI Key: HBFZQWHVSYYTGA-UHFFFAOYSA-N
  • Monoisotopic Mass: 942.460787724
  • Average Mass: 943.197
DBSALT001193
Categories
UNII1806D8D52K
CAS number50-48-6
WeightAverage: 277.4033
Monoisotopic: 277.183049741
Chemical FormulaC20H23N
InChI KeyKRMDCWKBEZIMAB-UHFFFAOYSA-N
InChI
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
Structured Indications
PharmacodynamicsAmitriptyline, a tertiary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is extremely sedating, and thus improvement of sleep patterns can be the first benefit of treatment. Amitriptyline exhibits strong anticholinergic activity, cardiovascular effects including orthostatic hypotension, changes in heart rhythm and conduction, and a lowering of the seizure threshold. As with other antidepressants, several weeks of therapy may be required in order to realize the full clinical benefit of amitriptyline. Although not a labelled indication, amitriptyline is widely used in the management of chronic nonmalignant pain (e.g., post-herpetic neuralgia, fibromyalgia).
Mechanism of actionAmitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 1AProteinunknown
inhibitor
HumanP08908 details
Delta-type opioid receptorProteinunknown
agonist
HumanP41143 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
High affinity nerve growth factor receptorProteinunknown
agonist
HumanP04629 details
BDNF/NT-3 growth factors receptorProteinunknown
agonist
HumanQ16620 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-1D adrenergic receptorProteinno
antagonist
HumanP25100 details
Alpha-2A adrenergic receptorProteinno
antagonist
HumanP08913 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Potassium voltage-gated channel subfamily KQT member 2Proteinno
inhibitor
HumanO43526 details
Potassium voltage-gated channel subfamily A member 1Proteinno
inhibitor
HumanQ09470 details
Potassium voltage-gated channel subfamily D member 2Proteinno
inhibitor
HumanQ9NZV8 details
Potassium voltage-gated channel subfamily D member 3Proteinno
inhibitor
HumanQ9UK17 details
Histamine H2 receptorProteinunknown
blocker
HumanP25021 details
Histamine H4 receptorProteinunknown
binder
HumanQ9H3N8 details
Sigma non-opioid intracellular receptor 1Proteinunknown
agonist
HumanQ99720 details
5-hydroxytryptamine receptor 2CProteinunknown
binder
HumanP28335 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
5-hydroxytryptamine receptor 1DProteinunknown
binder
HumanP28221 details
Mu-type opioid receptorProteinunknown
binder
HumanP35372 details
5-hydroxytryptamine receptor 1BProteinunknown
binder
HumanP28222 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
Potassium voltage-gated channel subfamily KQT member 3ProteinunknownNot AvailableHumanO43525 details
Beta adrenergic receptorProtein groupunknown
binder
Humannot applicabledetails
Related Articles
AbsorptionRapidly and well absorbed following oral administration (bioavailability is 30-60% due to first pass metabolism). Peak plasma concentrations occur 2-12 hours following oral or intramuscular administration.
Volume of distributionNot Available
Protein bindingVery highly protein bound (90% or more) in plasma and tissues
Metabolism

Exclusively hepatic, with first pass effect. Amitriptyline is demethylated in the liver to its primary active metabolite, nortriptyline.

SubstrateEnzymesProduct
Amitriptyline
NortriptylineDetails
Amitriptyline
E-10-HydroxyamitriptylineDetails
E-10-Hydroxyamitriptyline
E-10-HydroxynortriptylineDetails
E-10-Hydroxynortriptyline
Not Available
E-10-HydroxydesmethylnortriptylineDetails
Nortriptyline
E-10-HydroxynortriptylineDetails
Nortriptyline
Not Available
DesmethylnortriptylineDetails
Desmethylnortriptyline
E-10-HydroxydesmethylnortriptylineDetails
Route of eliminationVirtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with little unchanged drug appearing in the urine. 25-50% of a single orally administered dose is excreted in urine as inactive metabolites within 24 hours. Small amounts are excreted in feces via biliary elimination.
Half life10 to 50 hours, with an average of 15 hours
ClearanceNot Available
ToxicityLD50=350 mg/kg (in mice). Symptoms of overdose include abnormally low blood pressure, confusion, convulsions, dilated pupils and other eye problems, disturbed concentration, drowsiness, hallucinations, impaired heart function, rapid or irregular heartbeat, reduced body temperature, stupor, and unresponsiveness or coma. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableA > GIncrease risk of adverse effects22641028
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT Allele, homozygousPostural hypotension12082591
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > AThose with the AA or AG genotype are poor metabolizers of amitriptyline20531370
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TIncrease risk of side effects and decrease drug metabolism18070221
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TIncrease risk of side effects and decrease drug metabolism9918137
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Amitriptyline can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineAmitriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Amitriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Amitriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetamineAmitriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAmitriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amitriptyline.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Amitriptyline.Experimental
AbirateroneThe serum concentration of Amitriptyline can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Amitriptyline.Approved
AcenocoumarolAmitriptyline may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amitriptyline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amitriptyline.Approved
AcetaminophenThe serum concentration of Amitriptyline can be increased when it is combined with Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Amitriptyline.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Amitriptyline.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Amitriptyline.Approved
AgmatineAmitriptyline may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amitriptyline.Approved, Investigational
AlbendazoleThe serum concentration of Amitriptyline can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Amitriptyline can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amitriptyline.Vet Approved
AlfentanilThe serum concentration of Amitriptyline can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Amitriptyline.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Amitriptyline can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Amitriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amitriptyline.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amitriptyline.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmantadineThe serum concentration of Amitriptyline can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Amitriptyline.Approved, Investigational
Aminohippuric acidThe serum concentration of Amitriptyline can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Amitriptyline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Amitriptyline.Approved, Investigational
AmlodipineThe serum concentration of Amitriptyline can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Amitriptyline can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Amitriptyline.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amitriptyline.Experimental
AmphetamineAmitriptyline may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Amitriptyline can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Amitriptyline can be increased when it is combined with Amsacrine.Approved
AnagrelideAmitriptyline may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Amitriptyline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Amitriptyline can be increased when it is combined with Apixaban.Approved
ApomorphineAmitriptyline may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineAmitriptyline may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Amitriptyline can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Amitriptyline can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Amitriptyline can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amitriptyline.Approved, Investigational
ArmodafinilThe metabolism of Amitriptyline can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideAmitriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAmitriptyline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Amitriptyline.Approved
AsenapineAmitriptyline may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Amitriptyline can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Amitriptyline can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Amitriptyline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Amitriptyline can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Amitriptyline can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Amitriptyline can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amitriptyline.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Amitriptyline.Vet Approved
AzelastineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Amitriptyline can be increased when it is combined with Azelastine.Approved
AzithromycinAmitriptyline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Amitriptyline.Approved
BambuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Amitriptyline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Amitriptyline can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Amitriptyline can be increased when it is combined with Batimastat.Experimental
BedaquilineAmitriptyline may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Amitriptyline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Amitriptyline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Amitriptyline can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Amitriptyline can be increased when it is combined with Benzocaine.Approved
BenzphetamineAmitriptyline may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amitriptyline.Approved
BepridilThe serum concentration of Amitriptyline can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
BetaxololThe metabolism of Amitriptyline can be decreased when combined with Betaxolol.Approved
BethanidineAmitriptyline may decrease the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Amitriptyline can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Amitriptyline can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Amitriptyline can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Amitriptyline can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Amitriptyline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Amitriptyline can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amitriptyline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brexpiprazole.Approved
BrimonidineAmitriptyline may decrease the antihypertensive activities of Brimonidine.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amitriptyline.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline.Approved, Illicit
BromocriptineAmitriptyline may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Amitriptyline.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amitriptyline.Approved, Investigational
BuprenorphineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Amitriptyline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amitriptyline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Amitriptyline.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Amitriptyline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Amitriptyline.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amitriptyline.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amitriptyline.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amitriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amitriptyline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Amitriptyline.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Amitriptyline.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Amitriptyline.Approved
CandesartanThe serum concentration of Amitriptyline can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Amitriptyline can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Amitriptyline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Amitriptyline can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amitriptyline.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Amitriptyline.Approved
CariprazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Amitriptyline.Withdrawn
CarvedilolThe serum concentration of Amitriptyline can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Amitriptyline can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Amitriptyline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Amitriptyline can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Amitriptyline.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amitriptyline.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Amitriptyline can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amitriptyline.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amitriptyline.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amitriptyline.Approved
ChloroquineAmitriptyline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorphenamine.Approved
ChlorphentermineAmitriptyline may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineAmitriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Amitriptyline can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Amitriptyline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Amitriptyline can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Amitriptyline can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Amitriptyline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Amitriptyline can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amitriptyline.Approved
CimetidineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Amitriptyline can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amitriptyline.Approved, Vet Approved
CiprofloxacinAmitriptyline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineAmitriptyline may increase the vasopressor activities of Cirazoline.Experimental
CisaprideAmitriptyline may increase the arrhythmogenic activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Amitriptyline.Approved
CitalopramThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.Approved
ClarithromycinThe metabolism of Amitriptyline can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Amitriptyline can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Amitriptyline.Approved, Illicit
ClofazimineThe serum concentration of Amitriptyline can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Amitriptyline.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Amitriptyline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clonazepam.Approved, Illicit
ClonidineAmitriptyline may decrease the antihypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Amitriptyline can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amitriptyline.Approved, Illicit
ClotrimazoleThe metabolism of Amitriptyline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineAmitriptyline may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Amitriptyline can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amitriptyline.Approved
CocaineThe metabolism of Amitriptyline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amitriptyline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amitriptyline.Approved
ColforsinThe serum concentration of Amitriptyline can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Amitriptyline can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amitriptyline.Approved
CrizotinibAmitriptyline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Amitriptyline can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Amitriptyline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Amitriptyline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amitriptyline.Approved
DabrafenibThe serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Amitriptyline can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Amitriptyline can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Amitriptyline.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amitriptyline.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amitriptyline.Investigational
DarifenacinThe metabolism of Amitriptyline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Amitriptyline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Amitriptyline can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Amitriptyline.Approved
DeferasiroxThe serum concentration of Amitriptyline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Amitriptyline can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Amitriptyline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amitriptyline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine.Approved
DesloratadineThe serum concentration of Amitriptyline can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Amitriptyline.Vet Approved
DexamethasoneThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine.Approved
DexmedetomidineAmitriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amitriptyline.Approved
DextroamphetamineAmitriptyline may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amitriptyline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amitriptyline.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amitriptyline.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Amitriptyline.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Amitriptyline can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolAmitriptyline may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionAmitriptyline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amitriptyline.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amitriptyline.Approved
DigoxinThe serum concentration of Amitriptyline can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amitriptyline.Approved, Illicit
DihydroergotamineAmitriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amitriptyline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Amitriptyline.Illicit
DiltiazemThe metabolism of Amitriptyline can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Amitriptyline can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amitriptyline.Approved, Illicit
DipivefrinAmitriptyline may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Amitriptyline can be increased when it is combined with Dipyridamole.Approved
DisopyramideAmitriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Amitriptyline can be decreased when combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Amitriptyline.Approved, Investigational
DofetilideAmitriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronAmitriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneAmitriptyline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Amitriptyline.Vet Approved
DoxazosinThe serum concentration of Amitriptyline can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amitriptyline.Approved, Investigational
DoxorubicinThe serum concentration of Amitriptyline can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Amitriptyline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Amitriptyline.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Illicit
DronedaroneAmitriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amitriptyline.Experimental, Illicit
DroxidopaAmitriptyline may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Amitriptyline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.Approved
EcabetThe serum concentration of Amitriptyline can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amitriptyline.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amitriptyline.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amitriptyline.Approved
EfavirenzThe serum concentration of Amitriptyline can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Amitriptyline can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Amitriptyline can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amitriptyline.Approved, Investigational
EliglustatAmitriptyline may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Amitriptyline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Amitriptyline can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amitriptyline.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Amitriptyline can be decreased when it is combined with Enzalutamide.Approved
EphedraAmitriptyline may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Amitriptyline.Approved, Investigational
EpinephrineAmitriptyline may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergonovine.Approved
ErgotamineAmitriptyline may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amitriptyline.Approved, Investigational
ErythromycinAmitriptyline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Amitriptyline can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Amitriptyline can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amitriptyline.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Amitriptyline.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Amitriptyline can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Amitriptyline can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Amitriptyline can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amitriptyline.Approved
EthanolAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amitriptyline.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin.Approved
Ethyl biscoumacetateAmitriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amitriptyline.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amitriptyline.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amitriptyline.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Amitriptyline.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Amitriptyline.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Amitriptyline.Approved
EtomidateAmitriptyline may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Etoperidone.Approved
EtoposideThe serum concentration of Amitriptyline can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amitriptyline.Illicit, Vet Approved
EtravirineThe serum concentration of Amitriptyline can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amitriptyline.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Amitriptyline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Felbamate.Approved
FelodipineThe serum concentration of Amitriptyline can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amitriptyline.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Amitriptyline.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Amitriptyline.Approved
FlecainideAmitriptyline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin.Approved
FloxuridineThe metabolism of Amitriptyline can be decreased when combined with Floxuridine.Approved
FluconazoleAmitriptyline may increase the QTc-prolonging activities of Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amitriptyline.Approved, Illicit
FluindioneAmitriptyline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amitriptyline.Approved, Illicit
FluorouracilThe metabolism of Amitriptyline can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amitriptyline.Approved, Vet Approved
FlupentixolAmitriptyline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Amitriptyline can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Amitriptyline can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amitriptyline.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Amitriptyline.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Amitriptyline can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amitriptyline.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Amitriptyline can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amitriptyline can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Amitriptyline can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amitriptyline.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Amitriptyline.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amitriptyline can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amitriptyline.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amitriptyline is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Amitriptyline can be increased when it is combined with Gabexate.Investigational
Gadobenic acidAmitriptyline may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amitriptyline.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Amitriptyline.Approved, Investigational
GeldanamycinThe serum concentration of Amitriptyline can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Amitriptyline.Approved
GemfibrozilThe metabolism of Amitriptyline can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAmitriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Amitriptyline can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amitriptyline.Approved, Illicit
GlyburideThe serum concentration of Amitriptyline can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Amitriptyline can be increased when it is combined with Glycerol.Experimental
GM6001The serum concentration of Amitriptyline can be increased when it is combined with GM6001.Experimental
GoserelinAmitriptyline may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Amitriptyline can be increased when it is combined with Gramicidin D.Approved
GranisetronAmitriptyline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Amitriptyline.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Amitriptyline.Withdrawn
GuanabenzAmitriptyline may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineAmitriptyline may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amitriptyline.Approved, Illicit, Withdrawn
HaloperidolAmitriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amitriptyline.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amitriptyline.Approved, Illicit
HexobarbitalThe metabolism of Amitriptyline can be increased when combined with Hexobarbital.Approved
HirulogThe serum concentration of Amitriptyline can be increased when it is combined with Hirulog.Experimental
HydracarbazineHydracarbazine may increase the serotonergic activities of Amitriptyline.Approved
HydrocodoneAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline.Approved, Illicit
Hydroxyamphetamine hydrobromideAmitriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Amitriptyline.Approved
IbutilideAmitriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Amitriptyline can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Amitriptyline can be increased when it is combined with idraparinux.Investigational
IloperidoneAmitriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Amitriptyline can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Amitriptyline can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Amitriptyline.Approved
IndalpineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Amitriptyline can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Amitriptyline can be increased when it is combined with Indomethacin.Approved, Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Amitriptyline.Approved
IproclozideIproclozide may increase the serotonergic activities of Amitriptyline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Amitriptyline.Withdrawn
IrbesartanThe metabolism of Amitriptyline can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Amitriptyline.Approved, Investigational
IsavuconazoniumThe metabolism of Amitriptyline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amitriptyline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amitriptyline.Approved, Vet Approved
IsoflurophateThe serum concentration of Amitriptyline can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Amitriptyline can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoprenaline.Approved
IsradipineThe metabolism of Amitriptyline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Amitriptyline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Amitriptyline can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Amitriptyline.Approved, Vet Approved
IxazomibThe serum concentration of Amitriptyline can be increased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Amitriptyline can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Amitriptyline.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amitriptyline.Approved
KetoconazoleThe metabolism of Amitriptyline can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Amitriptyline.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Amitriptyline.Approved, Investigational
LansoprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Amitriptyline can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amitriptyline.Approved
LeflunomideThe metabolism of Amitriptyline can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Amitriptyline.Approved
LenvatinibAmitriptyline may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.Approved
LeuprolideAmitriptyline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Amitriptyline.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amitriptyline.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levodopa.Approved
LevofloxacinAmitriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amitriptyline.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amitriptyline.Approved
LevothyroxineThe serum concentration of Amitriptyline can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Amitriptyline can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Amitriptyline.Approved, Investigational
LiothyronineThe serum concentration of Amitriptyline can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Amitriptyline can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineAmitriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amitriptyline.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Amitriptyline.Illicit
LofexidineAmitriptyline may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Amitriptyline can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Amitriptyline can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Amitriptyline can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Amitriptyline can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amitriptyline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lorcaserin.Approved
LosartanThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Amitriptyline can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amitriptyline.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Amitriptyline.Investigational
LuliconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Amitriptyline can be increased when it is combined with Lumacaftor.Approved
LumefantrineAmitriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Amitriptyline.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Amitriptyline.Withdrawn
MebendazoleThe serum concentration of Amitriptyline can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Amitriptyline.Vet Approved
MefloquineThe serum concentration of Amitriptyline can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Amitriptyline can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amitriptyline.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Amitriptyline.Approved
MephedroneAmitriptyline may increase the stimulatory activities of Mephedrone.Investigational
MephentermineAmitriptyline may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amitriptyline.Approved, Vet Approved
MeprobamateThe serum concentration of Amitriptyline can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amitriptyline.Approved
MetaraminolAmitriptyline may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amitriptyline.Approved, Illicit
MethamphetamineAmitriptyline may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amitriptyline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amitriptyline.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Amitriptyline can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Amitriptyline.Approved
MethotrimeprazineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineAmitriptyline may increase the vasopressor activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amitriptyline.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methsuximide.Approved
Methylene blueAmitriptyline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.Approved, Investigational
MethylphenobarbitalThe metabolism of Amitriptyline can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amitriptyline.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amitriptyline.Approved, Investigational
MetyrosineAmitriptyline may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Amitriptyline can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Amitriptyline can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineAmitriptyline may increase the vasopressor activities of Midodrine.Approved
MifepristoneThe serum concentration of Amitriptyline can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Amitriptyline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Amitriptyline.Approved
MirtazapineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Amitriptyline can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Amitriptyline can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Amitriptyline can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAAmitriptyline may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Amitriptyline.Approved
ModafinilThe serum concentration of Amitriptyline can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amitriptyline.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Amitriptyline.Approved, Investigational
MoxifloxacinAmitriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amitriptyline.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amitriptyline.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amitriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Amitriptyline.Approved
NafamostatThe serum concentration of Amitriptyline can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Amitriptyline can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amitriptyline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amitriptyline.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
NaltrexoneThe serum concentration of Amitriptyline can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineAmitriptyline may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Naratriptan.Approved, Investigational
NaringeninThe serum concentration of Amitriptyline can be increased when it is combined with Naringenin.Experimental
NCX 4016The serum concentration of Amitriptyline can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Amitriptyline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Amitriptyline can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Amitriptyline can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Amitriptyline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amitriptyline can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Amitriptyline.Withdrawn
NicardipineThe metabolism of Amitriptyline can be decreased when combined with Nicardipine.Approved
NicorandilAmitriptyline may increase the hypotensive activities of Nicorandil.Approved
NicotineThe metabolism of Amitriptyline can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Amitriptyline can be decreased when it is combined with Nifedipine.Approved
NilotinibAmitriptyline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amitriptyline.Approved
NisoldipineThe serum concentration of Amitriptyline can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Amitriptyline can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Amitriptyline can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amitriptyline.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Amitriptyline.Approved
NorepinephrineAmitriptyline may decrease the antihypertensive activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Amitriptyline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Amitriptyline.Withdrawn
OfloxacinAmitriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Amitriptyline.Approved, Investigational
OlaparibThe metabolism of Amitriptyline can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Amitriptyline can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Amitriptyline.Approved
OmeprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronAmitriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Amitriptyline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Orciprenaline.Approved
OrphenadrineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amitriptyline.Investigational
OsimertinibThe serum concentration of Amitriptyline can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Amitriptyline can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amitriptyline.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amitriptyline.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amitriptyline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptyline.Approved, Illicit, Investigational
OxymetazolineAmitriptyline may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amitriptyline.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Amitriptyline can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Amitriptyline can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Amitriptyline can be increased when it is combined with Palbociclib.Approved
PaliperidoneAmitriptyline may decrease the antihypertensive activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Amitriptyline can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Amitriptyline.Approved, Investigational
PanobinostatThe serum concentration of Amitriptyline can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Pantoprazole.Approved
ParaldehydeAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the serotonergic activities of Amitriptyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amitriptyline.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.Approved
Peginterferon alfa-2bThe serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineAmitriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.Approved, Vet Approved
PentobarbitalThe metabolism of Amitriptyline can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
PerazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perazine.Investigational
PerflutrenAmitriptyline may increase the QTc-prolonging activities of Perflutren.Approved
PergolideAmitriptyline may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Amitriptyline can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amitriptyline.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amitriptyline.Approved
PethidineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Amitriptyline.Approved
PhenindioneAmitriptyline may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Amitriptyline.Withdrawn
PhenobarbitalThe metabolism of Amitriptyline can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Amitriptyline.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amitriptyline.Withdrawn
PhenprocoumonAmitriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
PhentermineAmitriptyline may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineAmitriptyline may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineAmitriptyline may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Amitriptyline can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Amitriptyline can be increased when it is combined with Phosphoramidon.Experimental
PimozideAmitriptyline may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe metabolism of Amitriptyline can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amitriptyline.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Amitriptyline.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Amitriptyline.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Amitriptyline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Amitriptyline can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Amitriptyline.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amitriptyline.Approved
PosaconazoleThe metabolism of Amitriptyline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleAmitriptyline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amitriptyline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Amitriptyline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amitriptyline.Approved, Illicit
PrazosinThe serum concentration of Amitriptyline can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amitriptyline.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amitriptyline.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amitriptyline.Approved
PrimaquineAmitriptyline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Amitriptyline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Amitriptyline can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Amitriptyline can be increased when it is combined with Probenecid.Approved
ProcainamideAmitriptyline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amitriptyline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amitriptyline.Approved, Vet Approved
ProgesteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineAmitriptyline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promethazine.Approved
PropafenoneAmitriptyline may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amitriptyline.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amitriptyline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Amitriptyline.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Amitriptyline.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amitriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Amitriptyline.Investigational
PseudoephedrineAmitriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Amitriptyline can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Amitriptyline can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Amitriptyline can be increased when it is combined with Quercetin.Experimental
QuetiapineAmitriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Amitriptyline can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineAmitriptyline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineAmitriptyline may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Amitriptyline can be decreased when combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Amitriptyline can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Amitriptyline can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Amitriptyline can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amitriptyline.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Amitriptyline.Approved
ReboxetineThe serum concentration of Amitriptyline can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Amitriptyline can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline.Approved
RemikirenThe serum concentration of Amitriptyline can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amitriptyline.Approved, Withdrawn
ReserpineThe serum concentration of Amitriptyline can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Amitriptyline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Amitriptyline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Amitriptyline can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amitriptyline.Approved, Investigational
RilpivirineThe serum concentration of Amitriptyline can be increased when it is combined with Rilpivirine.Approved
RisperidoneAmitriptyline may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritanserin.Investigational
RitobegronAmitriptyline may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine.Approved
RitonavirThe metabolism of Amitriptyline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Amitriptyline can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Rizatriptan.Approved
RolapitantThe serum concentration of Amitriptyline can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amitriptyline.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Amitriptyline.Vet Approved
RopiniroleAmitriptyline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline.Approved
RosiglitazoneThe metabolism of Amitriptyline can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineAmitriptyline may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amitriptyline.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amitriptyline.Experimental
SafrazineSafrazine may increase the serotonergic activities of Amitriptyline.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Amitriptyline is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Amitriptyline.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salmeterol.Approved
SaquinavirThe metabolism of Amitriptyline can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Amitriptyline can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Amitriptyline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Amitriptyline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Amitriptyline.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amitriptyline.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amitriptyline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amitriptyline.Approved, Vet Approved
SildenafilThe metabolism of Amitriptyline can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amitriptyline.Approved
SiltuximabThe serum concentration of Amitriptyline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Amitriptyline can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Amitriptyline can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Amitriptyline can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Amitriptyline.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amitriptyline.Approved, Investigational
SotalolAmitriptyline may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Amitriptyline.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Amitriptyline.Experimental
SpiraprilThe serum concentration of Amitriptyline can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Amitriptyline can be increased when it is combined with Spironolactone.Approved
St. John's WortThe metabolism of Amitriptyline can be increased when combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Amitriptyline can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Amitriptyline can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Amitriptyline can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.Approved, Investigational
SulfadiazineThe metabolism of Amitriptyline can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Amitriptyline can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Amitriptyline can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Amitriptyline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Amitriptyline.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Amitriptyline can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Amitriptyline can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Amitriptyline can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Amitriptyline can be decreased when it is combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Amitriptyline.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Amitriptyline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Amitriptyline.Approved
TelaprevirThe metabolism of Amitriptyline can be decreased when combined with Telaprevir.Approved
TelavancinAmitriptyline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Amitriptyline can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Amitriptyline can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amitriptyline.Approved
TemocaprilThe serum concentration of Amitriptyline can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Amitriptyline.Approved
TenofovirThe metabolism of Amitriptyline can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Amitriptyline can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Amitriptyline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Terbutaline.Approved
TerfenadineThe serum concentration of Amitriptyline can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Amitriptyline can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Amitriptyline can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Amitriptyline can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineAmitriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amitriptyline.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amitriptyline.Investigational
ThalidomideAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Amitriptyline can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Amitriptyline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Amitriptyline can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amitriptyline.Approved
ThiorphanThe serum concentration of Amitriptyline can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Amitriptyline can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amitriptyline.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amitriptyline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Amitriptyline.Approved
TiclopidineThe metabolism of Amitriptyline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Amitriptyline.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Amitriptyline.Approved
TipranavirThe metabolism of Amitriptyline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amitriptyline.Approved
TocilizumabThe serum concentration of Amitriptyline can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Amitriptyline can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Amitriptyline.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amitriptyline.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amitriptyline.Approved, Investigational
ToremifeneAmitriptyline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolAmitriptyline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Amitriptyline can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amitriptyline.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Amitriptyline.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Amitriptyline.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amitriptyline.Approved
TrifluoperazineThe serum concentration of Amitriptyline can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Amitriptyline can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Amitriptyline can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Amitriptyline can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Amitriptyline.Investigational
UbenimexThe serum concentration of Amitriptyline can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Amitriptyline is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Amitriptyline can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amitriptyline.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Amitriptyline.Approved
Valproic AcidThe serum concentration of Amitriptyline can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Amitriptyline can be decreased when combined with Valsartan.Approved, Investigational
VandetanibAmitriptyline may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Amitriptyline.Approved
VemurafenibThe serum concentration of Amitriptyline can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Amitriptyline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amitriptyline.Approved
VerapamilThe metabolism of Amitriptyline can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Amitriptyline can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amitriptyline.Approved, Investigational
VincristineThe serum concentration of Amitriptyline can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Amitriptyline can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Amitriptyline.Approved
VoriconazoleThe metabolism of Amitriptyline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vortioxetine.Approved
WarfarinAmitriptyline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Amitriptyline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Amitriptyline.Vet Approved
XylometazolineAmitriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Amitriptyline can be increased when it is combined with Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amitriptyline.Approved, Vet Approved
ZafirlukastThe metabolism of Amitriptyline can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amitriptyline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Amitriptyline.Approved
ZimelidineThe serum concentration of Amitriptyline can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneAmitriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Amitriptyline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amitriptyline.Approved, Investigational
ZolpidemAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amitriptyline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Amitriptyline.Approved
ZuclopenthixolAmitriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.
References
Synthesis Reference

Manfred Durr, Benedikt Gajdos, Klaus-Dieter Gneuss, Ekkehard Harhausen, Jurgen Seidel, “Pharmaceutical amitriptylin oxide preparation and process for its manufacture.” U.S. Patent US4567202, issued January 28, 1986.

US4567202
General References
  1. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y, Komatsu K, Ohba R, Oyake J, Hatakeyama N, Watanabe S: New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:42-6. [PubMed:15943846 ]
External Links
ATC CodesN06CA01N06AA09
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Watson laboratories inc
  • Astrazeneca pharmaceuticals lp
  • Bristol myers squibb co
  • Warner chilcott div warner lambert co
  • American therapeutics inc
  • Caraco pharmaceutical laboratories ltd
  • Copley pharmaceutical inc
  • Halsey drug co inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Ucb inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, film coatedOral
SyrupOral2 mg
KitTopical
TabletOral75 mg
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral
Kit
Prices
Unit descriptionCostUnit
Amitriptyline hcl powder7.34USD g
Amitriptyline hcl 150 mg tablet1.18USD tablet
Amitriptyline hcl 100 mg tablet0.66USD tablet
Amitriptyline hcl 75 mg tablet0.54USD tablet
Apo-Amitriptyline 75 mg Tablet0.38USD tablet
Amitriptyline hcl 50 mg tablet0.37USD tablet
Amitriptyline hcl 10 mg tablet0.3USD tablet
Apo-Amitriptyline 50 mg Tablet0.25USD tablet
Amitriptyline hcl 25 mg tablet0.21USD tablet
Apo-Amitriptyline 25 mg Tablet0.13USD tablet
Apo-Amitriptyline 10 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point187-189.5Tristram, E.W. and Tull, R.J.; US. Patent 3,205,264: September 7,1965; assigned to Merck & Co., Inc.
water solubility9.71 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.92HANSCH,C ET AL. (1995)
logS-4.46ADME Research, USCD
pKa9.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP5.1ALOGPS
logP4.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.51 m3·mol-1ChemAxon
Polarizability33.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.48 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9210000000-989cd234a8cdf04c5f69View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280 ]
  2. Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29. [PubMed:16032412 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Ushijima K, Sakaguchi H, Sato Y, To H, Koyanagi S, Higuchi S, Ohdo S: Chronopharmacological study of antidepressants in forced swimming test of mice. J Pharmacol Exp Ther. 2005 Nov;315(2):764-70. Epub 2005 Aug 3. [PubMed:16079297 ]
  5. Kalia M: Neurobiological basis of depression: an update. Metabolism. 2005 May;54(5 Suppl 1):24-7. [PubMed:15877309 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Onali P, Dedoni S, Olianas MC: Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14. [PubMed:19828880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Onali P, Dedoni S, Olianas MC: Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14. [PubMed:19828880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 ...
Gene Name:
NTRK1
Uniprot ID:
P04629
Molecular Weight:
87496.465 Da
References
  1. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K: Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009 Jun 26;16(6):644-56. doi: 10.1016/j.chembiol.2009.05.010. [PubMed:19549602 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in act...
Gene Name:
NTRK2
Uniprot ID:
Q16620
Molecular Weight:
91998.175 Da
References
  1. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K: Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009 Jun 26;16(6):644-56. doi: 10.1016/j.chembiol.2009.05.010. [PubMed:19549602 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed:14757140 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic in...
Gene Name:
KCNQ2
Uniprot ID:
O43526
Molecular Weight:
95846.575 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the firs...
Gene Name:
KCND2
Uniprot ID:
Q9NZV8
Molecular Weight:
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
Gene Name:
KCND3
Uniprot ID:
Q9UK17
Molecular Weight:
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Angus JA, Black JW: Pharmacological assay of cardiac H2-receptor blockade by amitriptyline and lysergic acid diethylamide. Circ Res. 1980 Jun;46(6 Pt 2):I64-9. [PubMed:6103762 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33. [PubMed:11179435 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Villard V, Meunier J, Chevallier N, Maurice T: Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci. 2011;115(3):279-92. [PubMed:21427517 ]
  2. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Di Matteo V, De Blasi A, Di Giulio C, Esposito E: Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci. 2001 May;22(5):229-32. [PubMed:11339973 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Wahlstrom A, Lenhammar L, Ask B, Rane A: Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. Pharmacol Toxicol. 1994 Jul;75(1):23-7. [PubMed:7971731 ]
  2. Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, Mico JA: Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology. 1987 Jun;26(6):531-9. [PubMed:3037421 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW: Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56. [PubMed:8522988 ]
  2. Sebben M, Ansanay H, Bockaert J, Dumuis A: 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport. 1994 Dec 20;5(18):2553-7. [PubMed:7696602 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to sy...
Gene Name:
KCNQ3
Uniprot ID:
O43525
Molecular Weight:
96741.515 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  3. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  6. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7. [PubMed:12228186 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Banerjee T, Singh SK, Kishore N: Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects. J Phys Chem B. 2006 Nov 30;110(47):24147-56. [PubMed:17125386 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46